Core Insights - IBM and Web Summit have launched a global sports-tech competition called the Sports Tech Startup Challenge, aimed at startups utilizing AI to innovate in sports [1][2][3] - The competition will feature regional events in Qatar, Vancouver, and Rio, culminating in a global finale at Web Summit Lisbon 2026 [1][6] - IBM aims to leverage its extensive experience in sports technology to foster innovation and support startups in the sports and entertainment sector [2][3] Company Initiatives - The Sports Tech Startup Challenge will unfold over a 12-month cycle, including mini-regional competitions where startups will pitch AI solutions [3][6] - Winners of the competition may receive a paid proof of concept valued at up to $100,000, mentorship from IBM experts, and evaluation for venture funding [3][4] - IBM is positioned as the Official AI Partner for all Web Summit 2026 conferences, enhancing its visibility and engagement in the sports tech arena [5][6] Industry Context - The sports industry is rapidly integrating AI technologies to enhance performance, generate new revenue streams, and improve fan experiences [2][4] - IBM has a long history of partnerships with major sports organizations, which positions it as a trusted technology partner in the sports sector [2][3] - The collaboration between IBM and Web Summit highlights the growing intersection of AI and sports technology, aiming to discover and support the next big innovations in the field [4][6]

CINCINNATI, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Workhorse Group, Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reminds all shareholders to vote “FOR” all proposals in connection with Workhorse’s upcoming Annual Meeting. Shareholders can visit www.VoteWKHS.com for more information on the transaction and how to vote. Your vote is important, no matter how many or how few shares you own. It is cri ...

Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatmentNew analysis examining effects of Rezdiffra treatment interruption underscores the need for sustained therapy to prevent disease progression CONSHOHOCKEN, Pa., Nov. ...

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEW ...

– Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315’s previously reported safety profile, these results highlight VP-315’s potential as a firs ...

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing Announced positive long-term safety and efficacy data with 1.5 to 2 years of follow-up from the Phase 1/2 PRISM clinical trial in wet AMD Completed equity offering providing net proceeds of ~$93 million Announced up to $11 million equity investment from the Cystic Fibrosi ...

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. T ...

Redfin reports 22% of U.S. home listings are affordable to the typical U.S. military veteran using a VA loan SEATTLE--(BUSINESS WIRE)--Nationwide, just over one in five (21.8%) home listings are affordable to the typical U.S. military veteran using a VA loan, while 26.5% are affordable to the typical veteran using a conventional loan. That's according to a new report from Redfin, the real estate brokerage powered by Rocket. Affordability has improved slightly over the last two years. Just 20.2% of listings ...

While more boomers are working beyond their 65th birthday and many will live to 85 or beyond, not all will spend their final years in good health. Picture Dave, 66, and his wife Susan, 62 — diligent savers who have six months of emergency savings in a high-yield account along with an impressive $2-million nest egg in 401(k)s, which they hoped to draw down at a comfortable 4% annually, or $6,700 a month in their golden years. Must Read They’ve planned for everything … except Susan’s recent MS diagnosis. ...

Forward contract cover locked in for 100% of 2025, 96% of 2026, and 74% of 2027. Maximizing strategic optionality while also returning capital to shareholders. Annualized dividend to increase to $2.50 per Class A Common Share. ATHENS, Greece, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE: GSL) (the “Company”, “Global Ship Lease” or “GSL”), an owner of containerships, announced today its unaudited results for the three and nine-month periods ended September 30, 2025. Third Quarter of 2025 a ...